United States: Federal Circuit Affirms The PTAB's Decision Finding The Patent Claims Unpatentable As Obvious Where The Patent Owner Did Not Demonstrate That The Board Violated The Administrative Procedure Act Requirements Of Notice And An Opportunity To Respond

NOVARTIS AG, MITSUBISHI PHARMA CORP., v. TORRENT PHARM. LTD.: April 12, 2017. Before Taranto, Chen, and Stoll. (precedential).


  • The Patent Trial and Appeal Board did not violate the requirements of notice and an opportunity to respond found in the Administrative Procedure Act when it relied on a prior art reference in the final written decision because the discussion of the reference in the final written decision was not inconsistent with its review of the reference in the institution decision.
  • In order for objective indicia evidence to be accorded substantial weight by the PTAB, a nexus must exist between the evidence and the merits of the claimed invention. If commercial success is due to an element in the prior art, there is no nexus. If the feature that creates the commercial success was known in the prior art, the success of the claimed invention is not probative.

Procedural Posture:

Novartis AG appealed the Final Written Decision of the Patent Trial and Appeal Board in two consolidated inter partes review proceedings finding all of the patent claims unpatentable as obvious. CAFC affirmed.


  • APA Due Process: The Administrative Procedure Act imposes certain procedural requirements on agencies, including that in an inter partes review proceeding, the PTAB must provide the patent owner with timely notice of "the matters of fact and law asserted," and an opportunity to submit facts and argument. Novartis argued that the Board violated these requirements of notice and an opportunity to respond when the Board used the Sakai reference as part of its motivation to combine analysis in the Final Written Decision. Novartis argued that the Board ruled Sakai entirely out of the case in the Institution Decision and that Novartis consequently relied on that ruling and submitted a "vastly different" record than it would have if it had known Sakai was still a live issue. The CAFC disagreed with Novartis that the Board ruled Sakai out of the case in the Institution Decision, finding instead that the Board did not find that Sakai anticipated, but did find it relevant to one of skill in the art in deciding which excipients to use in formulating a solid oral dosage form of fingolimod. The CAFC found that the Board's discussion of Sakai in the Final Written Decision was not inconsistent with its review of Sakai in the Institution Decision. In addition, the CAFC found that the petitioners repeatedly referenced Sakai as evidence that the claims would have been obvious to a person skilled in the art, and that both sides' experts went into significant detail in their post-institution declarations discussing Sakai and its applicability to the motivation to combine inquiry. The Board rejected Novartis' APA challenge, and found no violation of the APA with respect to the Board's discussion of Sakai in the Final Written Decision.
  • Motivation to Combine: Novartis argued that the Board erred in its motivation to combine analysis because it failed to read the prior art as a whole and overlooked critical evidence of mannitol's known disadvantages as an excipient for solid compositions. Novartis argued that it pointed out mannitol's negative properties, and that because the Board did not expressly state that it was weighing the negatives against mannitol's positives, the Board's motivation to combine analysis was legally flawed. The CAFC found that the Board expressly addressed one of mannitol's negative properties in the Final Written Decision. Moreover, the CAFC found that the Board's consideration of mannitol's negative properties in the Final Written Decision was commensurate with Novartis' presentation of those issues to the Board in its Patent Owner Response. Thus, the CAFC was not persuaded that Novartis presented its arguments against the use of mannitol in such a way that it would be appropriate to find fault in the Board's treatment of those arguments in the Final Written Decision. The CAFC concluded that substantial evidence supported the Board's finding that, despite mannitol's potentially negative characteristics, it was nevertheless a valid consideration and one skilled in the art would have been motivated to combine mannitol with fingolimod as claimed.
  • Unexpected Results / Waiver: Novartis argued that the Board erred when it grouped several dependent claims with their independent claims when considering Novartis' unexpected results evidence. The CAFC noted that the argument Novartis raised with the Board during the IPR (that the combination of fingolimod and mannitol stabilized low dose compositions) was different than Novartis' characterization of that argument on appeal. The CAFC found that during the IPR Novartis focused its arguments on the mere combination of fingolimod and mannitol, without regard to any dosage amount. Moreover, Novartis conceded at oral argument that the focus of its unexpected results argument was that fingolimod was unexpectedly stable across the entire dosage range. The CAFC thus found that Novartis had waived the argument.
  • Nexus: Novartis argued that the Board erred as a matter of law in its analysis of the "nexus" requirement with respect to the objective evidence of nonobviousness. Novartis argued that, as a matter of law, a feature that is known in the art but not actually available to the market, i.e. in commerce, cannot be used to disprove Novartis' attempts to establish a nexus based on that claimed feature. The CAFC disagreed, finding that in evaluating whether the requisite nexus exists, the identified objective indicia must be directed to what was not known in the prior art, which may be the novel combination or arrangement of known individual elements. Novartis' nexus argument for its objective indicia evidence was based solely on the premise that Gilenya was the first commercially-available solid oral multiple sclerosis treatment. The Board found evidence that a prior art reference suggested treating multiple sclerosis using a solid oral form of fingolimod. The CAFC found that the fact that Gilenya was the first to receive FDA approval for commercial marketing did not overcome the fact that solid multiple sclerosis compositions were already known. The CAFC agreed with the Board that Novartis' proffered evidence is not probative of the nonobviousness inquiry.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions